NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating ...

The deal size was increased to $416.5M from $300M and priced below last closing price of $25.57. Jefferies, Goldman Sachs, Leerink, TD Cowen, ...

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...

NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...